The current financial score of Lexicon Pharmaceuticals Inc is 5.48. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 692.00K, representing a year-over-year decrease of 97.60%, while its net profit experienced a year-over-year decrease of 1077.09%.
The current valuation score of Lexicon Pharmaceuticals Inc is 8.41. Its current P/E ratio is -28.50, which is -100.00% below the recent high of 0.00 and -29.73% above the recent low of -36.97.
The current earnings forecast score of Lexicon Pharmaceuticals Inc is 7.60. The average price target is 3.86, with a high of 6.00 and a low of 2.00.
The current price momentum score of Lexicon Pharmaceuticals Inc is 4.59. Currently, the stock price is trading between the resistance level at 2.33 and the support level at 1.81, making it suitable for range-bound swing trading.
The current institutional shareholding score of Lexicon Pharmaceuticals Inc is 5.00. The latest institutional shareholding proportion is 67.79%, representing a quarter-over-quarter decrease of 1.30%. The largest institutional shareholder is James Simons, holding a total of 1.13M shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
The current risk assessment score of Lexicon Pharmaceuticals Inc is 5.22. The company's beta value is 1.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.